The simplicity of the ddPCR-TERT assays over other complex urine tests such as the UroSEEK or the test developed by Dahmcke et al. [22], that combines DNA mutation testing (TERT and FGFR3) and methylation biomarkers (SALL3, ONECUT2, CCNA1, BCL2, EOMES, and VIM), would considerably ease the clinical implementation of uTERTpm testing into routine clinical practice for the early detection of BC, especially in LMICs where access to cystoscopy facilities may often represent a barrier to early BC diagnosis. This evidence concerns the gene CCNA1 and breast cancer.